# The Surge of Dengue Cases during COVID-19 in Indonesia

*by* Muhammad Miftahussurur

# The Surge of Dengue Cases during COVID-19 in Indonesia

Short title: Dengue and Covid-19

Retno Budiarti[1], Wienta Diarsvitri[2], Brian Eka Rachman[3], Muhammad Miftahussurur[4]

[1] Department of Microbiology, Faculty of Medicine, Universitas Hang Tuah, Surabaya 60111, Indonesia

[2] Department of Community Health, Faculty of Medicine, Universitas Hang Tuah, Surabaya 60111, Indonesia

[3] Division of Tropical and Infectious Disease, Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya 60286, Indonesia

[4] Gastroentero-Hepatology Division, Department of Internal Medicine, Faculty of Medicine-Dr. Soetomo Teaching Hospital, Universitas Airlangga, Surabaya 60286, Indonesia

[5] Institute of Tropical Disease, Universitas Airlangga, Surabaya 60115, Indonesia

**Corresponding author:**

Muhammad Miftahussurur MD, Ph.D.

Gastroentero-Hepatology Division, Department of Internal Medicine, Faculty of Medicine-Dr. Soetomo Teaching Hospital, Universitas Airlangga, Surabaya

Jalan Mayjend Prof. Dr. Moestopo No. 6-8 Surabaya 60131, Indonesia.

Tel: +6231-502-3865; Fax: +6231-502-3865

1

E-mail: miphto@yahoo.co.id; muhammad-m@fk.unair.ac.id


Or


**Retno Budiarti, MD**

Department of Microbiology, Faculty of Medicine, Universitas Hang Tuah, Surabaya 60111,

Indonesia

Jalan Gadung No. 1, Jagir, Wonokromo, Surabaya, 60111, Indonesia

Email: dr.retnobudiarti74@gmail.com

2

**Abstract**

**Background:** Most healthcare resources in Indonesia have been engulfed by COVID-19 pandemic, and less attention has been given to the rising cases of dengue that has been endemic in many areas of Indonesia.

**Aim:** This study aimed to review the immunopathogenesis of dengue and COVID-19 infection, as well as their prevention strategies.

**Methods:** This study is a narrative review based on the research articles and reports published between 2010-2020. A total of 60 articles and reports were obtained and after careful consideration 49 articles and reports were used as references of this study.

**Results:** The immune response in DENV and SARS-CoV-2 infections aims to eliminate the virus, but it causes an increase in inflammatory mediators (cytokine storm) which can increase vascular permeability and organ damage. Secondary infection of DENV with different strains may allow the occurrence of ADE. The possibility of ADE in SARS-CoV infection has been studied in vitro and in animal studies. DENV and SARS-CoV-2 infections have antigenic similarities and trigger memory B cells. The cross reactions between SARS-CoV-2 antibodies and DENV antigens may cause false positive on rapid dengue infection serological tests.

**Conclusion:** The prevention and control of DENV and SARS-CoV-2 infections are based on the mode of transmission, and people should comply to the related health protocols.

3

## Introduction

On March 2, 2020, the first two confirmed COVID-19 cases were registered in Indonesia [1]. On March 11, 2020, WHO declared COVID-19 as a pandemic, after more than 118,000 cases had spread to more than 110 countries [2]. The disease has spread fast to almost all parts of Indonesia, causing a massive strain on Indonesia's healthcare system along with a surge of COVID-19 cases and deaths. Based on the rising fatalities and extensive socio-economic impact, on April 13, 2020, the President declared COVID-19 as a national disaster [3].

While most healthcare resources in Indonesia have been engulfed by COVID-19 pandemic, less attention has been given to the rising cases of dengue, despite a history that Indonesia had the highest cases of dengue haemorrhagic fever (DHF) in South East Asian region from 1968-2009 [4]. Dengue fever has been originally reported in Surabaya in 1968 in Indonesia, with 58 people being affected and 24 dead, resulting in 41.38 percent case fatality rate (CFR). Dengue has spread to many areas in Indonesia and has become a public health concern since then [4].

In Indonesia, DHF usually reaches its peak around March and dwindles in subsequent months, which are transition months between rainy season and dry season. However, during COVID-19 pandemic, DHF cases in Indonesia have still been increasing with reports of more than 71,663 cases and 459 deaths from January to July 2020, even though the recorded cases and deaths were lower compared to reports from January to July 2019 with 112,954 cases and 751 deaths [5].

As of July 9, 2020, ten provinces reported highest number of DHF cases in 2020: West Java (10,772 cases), Bali (8,930 cases), East Java (5,948 cases), East Nusa Tenggara (5,539 cases), Lampung (5,135 cases), Special Capital Region of Jakarta (4,227 cases), West Nusa Tenggara (3,796 cases), Central Java (2,846 cases), Special Region of Yogyakarta (2,720 cases), and Riau (2,255 cases) [5]. As of July 9, 2020, five of the ten provinces that reported

4

highest cases of DHF also reported highest cases of COVID-19, i.e., East Java (CFR 7.3%), Special Capital Region of Jakarta (CFR 5.0%), Central Java (CFR 4.3%), West Java (CFR 3.8%), and Bali (CFR 1.3%) [6]. The double burden of diseases has baffled health workers as both DHF and COVID-19 viruses might have similar symptoms in early stages and both battle on two fronts of healthcare need. Therefore, this study aimed to review the immunopathogenesis of dengue and COVID-19 infection, as well as their prevention strategies.

**Search Strategy**

This study is a narrative review based on the research articles and reports related to dengue virus, immunopathogenesis of dengue, epidemiology of dengue in Indonesia, dengue prevention, COVID-19 virology and pathogenesis, epidemiology of COVID-19 in Indonesia, and COVID-19 prevention that were published between 2010-2020. References from published articles were also included in the review, as long as they were published between 2010-2020. We excluded expert's point of views. A total of 60 articles and reports were obtained and after careful consideration 49 articles and reports were used as references of this study.

**Epidemiology of Dengue Haemorrhagic Fever in Indonesia**

Around half a century (1968-2017), there was an annual increase of incidence rate (IR) of DHF in Indonesia (red curve in Figure 1), from around 0.05 cases per 100,000 person-years in 1968 to around 77.96 cases per 100,000 person-years in 2016; with peak of cyclic pattern prevailing nearly 6-8 years [7]. In contrast, the annual CFR of DHF has decreased subsequently (blue curve in Figure 1), from more than 20% in 1968 to 0.79% in 2016 [7].

5

Figure 1. Incidence rate (per 100,000 person-years) and case fatality rate (%) of dengue haemorrhagic fever in Indonesia from 1968 to 2017 [7].

From 2011 to 2020, West Java had the highest average number of DHF cases annually [7-8]. The four months data from January to April 2017 to 2020 revealed the highest number of DHF cases was in 2019, while the highest DHF CFR was in 2018 [8].

Table 1. Number of DHF cases, deaths and CFR from January to April (four months)

| Year | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|
| Number of cases | 39,213 | 26,441 | 83,059 | 45,256 |
| Number of deaths | 206 | 218 | 625 | 297 |
| CFR | 0.53% | 0.82% | 0.75 | 0.66% |

**Dengue Virus**

Dengue virus (DENV) is one of Arthopod borne viruses (arbo virus), in which its transmission is mediated by mosquito vectors, *Aedes* spp. Dengue virus belongs to the *Flaviviridae*, a family of positive, single-stranded, enveloped RNA viruses [9], consists of four serotypes, namely DEN-1, DEN-2, DEN-3 and DEN-4 [10]. Further, dengue virus is endemic in more than 100 tropical and subtropical countries where its vectors reside [11], with around 100 million symptomatic cases being reported every year [12].

Dengue viral genome component comprises of genes that encode structural proteins and non-structural proteins. The structural protein genes contain codes to form protein M (membrane), C (capsid) and E (envelope); and these outer proteins will bind to human antibodies. In contrast, the non-structural protein genes contain codes to form enzymes that are needed for virus replication [13].

**Immunopathogenesis of Dengue Virus.**

Dengue viruses, including keratinocytes and Langerhans in cells, are replicated in the skin cells after infection [14]; which then trigger various host innate immune responses, including macrophage, Natural Killer cells (NK cells), as well as the secretion of interferon 1 (IFN 1) by infected cells, that prevent the entry of viruses into other cells [15–17]. When the innate immune system fail to destroy the virus, the adaptive or specific immune system, including CD4 T lymphocytes (T helper cells), CD8 T lymphocytes (cytotoxic T cells) and B lymphocyte cells will take a role. Macrophages that unable to kill the virus will present the virus peptide component on the surface of the cell to cytotoxic T cells through Major Histocompatibility Complex I (MHC I). The bonding complex is formed between receptors on the surface of cytotoxic T cells, MHC molecules, virus peptides and macrophage cells; which acts as APC (antigen presenting cells). After the bonding complex occurs, CD8 cells will produce cytokines,

such as perforin, granzime, granulosin, IFN 1 and tumor necrosis factor alpha (TNFα), which will cause macrophage to undergo apoptosis [18–20].

In addition, macrophages also present viral peptides to T helper cells, where the bonding complex that occurs between APC cells, MHC molecules and T helper cells will cause T helper cells to differentiate into Th1 and Th2 to produce mediator cytokine inflammation IL-4, IL-5, IL-10, IL-12, and IFN γ. The cytokines will help the macrophages to kill the virus. CD4 cells will also differentiate B lymphocytes to proliferate into plasma cells, in which plasma cells will produce anti-dengue antibodies that will neutralize the virus [20].

Dengue may also infect mast cells, causing degranulation, which may activate melanoma differentiation-associated protein 5 (MDA5) and retinoic acid-inducible gene I (RIG-I). Both MDA5 and RIG-I will activate the transcription of nuclear factor kappa-light-chain-enhancer of activated B cell (NFκB) and produce IFN 1. Therefore, IFN 1 is a natural antiviral as described above. Moreover, mast cell degranulation will cause these cells to release several inflammatory mediators, such as chymases, leukotrienes, tryptases and vascular endothelial growth factor (VEGF), which can increase vascular permeability and cause vascular leakage [21-22].

The innate and adaptive immune response phases will determine the clinical symptoms that appear in infected patients. If both systems successfully kill the dengue virus, then there will be a low viremia or no virus, so that the patient does not show clinical symptoms (subclinical). However, if the virus remain in moderate amounts (moderate viremia), then the clinical symptoms appear as dengue fever. If the virus escapes from the immune system and lead to severe viremia, then the clinical symptoms appear as dengue hemorrhagic fever, with life-threatening emergency symptoms, such as bleeding, shock, and death [10-24].

Dengue virus is able infect macrophage cells, dendritic cells and mast cells. The virus is also able to infect endothelial cells. The infected endothelial cells will activate NFκB, which

will cause apoptosis in these endothelial cells. The demise of endothelial cells by apoptosis will increase blood vessel permeability and cause plasma and red blood cell leakage, which is clinically seen as a bleeding [25].

Antibodies in dengue infection are produced by plasma cells derived from differentiation of B lymphocytes, by activation of CD4 cells through the intermediary molecule MHC II. Anti dengue antibodies, part of host humoral pathways, are specific to dengue virus and will bind as lock and key to neutralize the virus [10].

The above mechanism occurs in the first infection by dengue virus and secondary infection from the same serotype. In the case of a secondary infection, however, which may be caused by a particular Dengue virus serotype, the antibodies formed from the prior infection may not neutralize the second, but cause the fragment crystallisable region (Fc) antibody fragment on the macrophage cell surface to be bound to the antibody receivers. This attachment causes the entry of dengue virus into these cells and causes massive viral replication, increase in viral load, and release of several inflammatory mediators, which is referred to as antibody dependent enhancement (ADE). The occuring clinical manifestations are dengue hemorrhagic fever, dengue shock syndrome or death [26-27].


**Epidemiology of COVID-19 in Indonesia**

Figure 2. Number of COVID-19 confirmed cases, recover, death, RR and CFR [28]

Figure 2 depicts number of COVID-19 confirmed cases, recover, death, recovery rate (%) and case fatality rate (%) reported from March 2, 2020 to July 28, 2020. There was an increase in the number of confirmed cases from the first cases reported on March 2, 2020 to July 28, 2020 following the increase number of people that have been tested with RT PCR. There was a decrease in attack rate (AR = percentage of confirmed cases by population size per 100,000 people) from 0.7% on March 2, 2020 to 22.2% on July 2, 2020. The estimated current population of Indonesia in 2020 is 267,700,000 people. There was a decrease of case positivity rate (CPR = percentage of confirmed cases by number of specimens tested) from 24.1% on April 2, 2020 to 11.7% on July 2, 2020. There was an increase of case recovery rate (CRR = percentage of recover cases by confirmed cases) from 6.3% on April 2, 2020 to 45.4% on July 2, 2020. There was a decrease of case fatality rate (CFR = percentage of death cases by confirmed cases) from 9.5% on April 2, 2020 to 5.0% on July 2, 2020 [28].

**SARS-CoV-2**

10

Virus causing COVID-19 (SARS-CoV-2) is Corona strains affecting humans following severe acute respiratory syndrome-related coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). The genome of the coronavirus occupies four large protein areas: spike (S), nucleocapsid (N), membrane (M), and envelope (E). S protein is responsible for the entry of viruses into cells which express the enzyme 2 (ACE2) receptors that convert angiotensin. About 75% of the SARS-CoV-2 genome is identical to the SARS-CoV genome, in which both viruses use ACE2 receptors to infect epithelial and endothelial barrier cells of the airway mucosa [29].

The SARS-CoV outbreak that emerged in 2003 and MERS-CoV outbreak in 2012 were originated from bats [30]. Over time, mutations occur that cause possible transmission between bats to camels and other intermediate hosts, then transmission continues from animals to humans (zoonotic transmission) and finally from humans to humans [31].

**Immunopathogenesis of SARS-CoV-2**

The immune response to SARS-CoV-2 is not much different from dengue infection, in which the innate immune system collaborates with the cellular immune system to kill the virus. When a virus infects macrophage cells (Figure 3A), NK cells as part of the innate immune system lyse both the infected macrophage cells and the viruses inside them. If macrophages fail to lyse the virus, they will activate CD4 cells. CD4 cells will differentiate into Th2 and Th1. Th1 cells will release IFN $\gamma$ and IL2 as well as granzyme and several other inflammatory mediators to strengthen the role of macrophage cells. Meanwhile, Th2 cells will help differentiate B lymphocyte cells into plasma cells and produce specific antibodies for this virus and then act as neutralizing antibodies [32-33].

One main feature of a SARS-CoV-2 infection is the emergence, by the release of proinflammatory cytokines and chemokines by immune cells, of cytokine storms that create an

unregulated systemic inflammatory response. High levels of cytokines and chemokines have been detected in COVID-19 patients, including interleukin IL1-β, IL1RA, IL7, IL8, IL9, IL10, basic FGF2, GCSF, GMCSF, IFNγ, IP10, MCP1, MIP1α, MIP1β, PDGFB, basic TNFα, and VEGFA. Cytokine storms cause extreme inflammatory responses causing ARDS, multiple organ failure, and death [29].

**Is there a role of ADE in COVID 19 infection?**

There are no available clinical data to date showing the mechanism of ADE for SARS-CoV-2. However, previous coronavirus infections that heal with different types of SARS-CoV-2 may indicate the possibility of ADE, based on in vitro and animal models infected with SARS-CoV and MERS-CoV. The non-neutralizing antibodies recognize the S protein of the virus and bind it to the receptor. The non neutralizing antibody-Fc receptor complex will then cause viruses to enter cells that express IgG Fc receptors [27]. Furthermore, it was proposed that anti-MERS-CoV specific antibodies and SARS-CoV specific antibodies may mediate the attachment of the SARS-CoV to monocyte cells that express Fc receptors (FcR), thereby triggering structural changes in MERS-CoV antibodies that allow the virus to enter the monocyte cells, replicate and increase the amount of virus [34].

Other studies suggest that the antibodies produced from the SARS-CoV vaccine actually increase the infection process in B lymphocyte cells from animal models of hamsters [26]. In SARS-CoV infection, ADE can be mediated by the involvement of FcR expressed by immune cells, such as monocytes and macrophages. SARS-CoV specific antibodies may allow viruses to enter cells that express FcR. This FcR-mediated process is different from the cellular pathway for virus entry mediated by the ACE2 receptor. However, macrophage infection through ADE does not produce a productive virus in replication. In contrast, the internalization

of the viral immune-antibody complex via FcR in macrophages causes an increase of TNF and IL-6 production, which can increase inflammation (Figure 3C) [35].



Figure 3. Potential role of Antibody-Dependent Enhancement (ADE) during SARS-CoV-2 infection. A. When SARS-CoV-2 infects macrophage cells, their S protein binds to angiotensin-converting enzyme 2 receptor (ACE2-R) and transmembrane serin protease 2 (TMPRSS2) and leading them into the macrophage cytoplasm. NK cells then lyse both the SARS-CoV-2 infected macrophage cells and the viruses itself. Macrophages also activate naïve CD4+ T-cells, which differentiate into Th2 and Th1. Th1 cells will release IFN γ and IL2 as well as granzyme and several other inflammatory mediators. Whereas Th2 cells will help B

lymphocyte cells differentiation into plasma cells and produce specific antibodies. B. On second infection of the same strain, the high titre of specific antibodies will neutralize the virus. C. However, in reinfection cases of different SARS-CoV-2 strain or from immunization settings, the non-neutralizing antibodies recognize the S protein of the virus and bind it to the receptor. The non-neutralizing antibody-Fcγ receptor complex will then let the virus to enter cells that express IgG Fcγ receptors without binding to ACE2 receptor. After engulfing into the cells, the virus will be separated from the non-neutralizing antibody/SARS-CoV-2 complex because of the weak affinity and the virus will escape from lysosomal breakdown. Furthermore the virus will replicate more and prompt further pro-inflammatory response.

**Dengue Fever and COVID-19**

Dengue fever and COVID-19 may have similar clinical symptoms in early stages and similar laboratory features [36-37]. A rapid serological test for dengue (IgG anti-dengue) has been shown in two patients in Singapore to be false positive, and they were later reported to have a SARS-CoV-2 positive reverse transcription polymerase chain reaction (RT PCR)[38]. False-positive results in serological tests for dengue fever are possibly due to antigenic similarities between dengue virus and SARS-CoV-2, so they are able to form antibodies that will be detected by rapid serological tests for dengue virus. In addition, due to the similarity of antigenic structure, SARS-CoV-2 can trigger the production of anti-DENV antibodies from immunological memory of T and B cells derived from previous exposure to the DENV virus. The anti-DENV antibodies against dengue may cause a false positive result of rapid dengue test and fail to consider COVID-19 infection, which lead to serious implication for both patients and public health [38].

**Preventing DENV and SARS-CoV-2 Transmission**

14

DENV is primarily transmitted by female *Aedes aegypti* and *Aedes albopictus*, which are endemic almost in all areas of Indonesia [39]. DHF prevention and control focus on breaking the life cycle of mosquito vectors with biological, physical, and chemical approaches that have been part of national health programs and have been introduced to the community since 1968 [40]. The popular physical approach of DHF prevention in the community is to eradicate mosquito's breeding place by draining water reservoirs once a week, covering water reservoir, and recycling used containers [41].

In contrast, SARS-CoV-2 may be transmitted primarily through contact, respiratory droplet (>5-10 μm in diameter) and droplet nuclei (aerosol, ≤ 5 μm in diameter) [42] when an infected person talks, coughs, sings or sneezes [43]. However, it may also be possible to be transmitted through airborne [44], fomite (contaminated services) [45], fecal-oral [46], bloodborne, mother-to-child, and animal-to-human [47].

The prevention of SARS-CoV-2 are based on the mode of transmission and the approaches have been introduced to the community. The health protocols to prevent the transmission of SARS-CoV-2 have been applied in the work places, schools, health care facilities, homes, and other public places in Indonesia [49], and it is expected that people will adhere to the health protocols.

**Conclusion**

The immune response in DENV and SARS-CoV-2 infections aims to eliminate the virus, but it causes an increase in inflammatory mediators (cytokine storm), which can increase vascular permeability and organ damage. Secondary infection of DENV with different strains may allow the occurrence of ADE. The possibility of ADE in SARS-CoV infection has been studied in vitro, and in animal studies. DENV and SARS-CoV-2 infections have antigenic similarities, and trigger memory B cells. The cross reactions between SARS-CoV-2 antibodies and DENV

15

antigens may cause false positive on rapid dengue infection serological tests. The prevention and control of DENV and SARS-CoV-2 infections are based on the mode of transmission, and people should comply to the related health protocols.

**Acknowledgment**

The authors would like to express their gratitude to Danang Limanto for illustration assistance.

**References**

[1]    Ministry of Health of the Republic of Indonesia. "Recent Situation of Novel Coronavirus (COVID-19), Update1 March 2020." Jakarta; . 2020.

[2]    VERTIC. "Addendum to Fact Sheet 15 on National Implementation Measures for the International Health Regulations 2005 (IHR). COVID-19 as a Public Health Emergency of International Concern (PHEIC) under the IHR." London; . 2020.

[3]    WHO Indonesia. "Coronavirus Disease 2019 (COVID-19) Situation Report - 4." Jakarta; . 2020.

[4]    Soepardi J., R. Brahim, Hasnawati, N.D. Anggraeni, and F. Ismandari. "Dengue Hemorrhagic Fever in Indonesia 1968-2009 (Demam Berdarah Dengue di Indonesia Tahun 1968-2009)." *Buletin Jendela Epidemiologi*. vol. 2, pp. 1–13. 2010.

[5]    Ministry of Health of the Republic of Indonesia. "Until July, dengue cases in Indonesia reached 71 thousand (Hingga Juli, Kasus DBD di Indonesia Capai 71 Ribu)." Jakarta: Ministry of Health of the Republic of Indonesia,; p. 1. 2020.

[6]    Ministry of Health of the Republic of Indonesia. "Recent Situation of Novel Coronavirus (COVID-19). Data reported until 9 July 2020" [Internet]. Jakarta; . 2020. [Available from:

https://infeksiemerging.kemkes.go.id/download/Situasi_Terkini_100720.pdf

[7]     Harapan H., A. Michie, M. Mudatsir, R.T. Sasmono, and A. Imrie. "Epidemiology of dengue hemorrhagic fever in Indonesia: Analysis of five decades data from the National Disease Surveillance." *BMC Research Notes*. vol. 12, pp. 350. 2019.

[8]     Ministry of Health of the Republic of Indonesia. "Dengue Haemorrhagic Fever. Cases and deaths due to DHF (January to 21 April 2020)." Jakarta; . 2020.

[9]     Centers for Disease Control and Prevention (CDC). "Viral Hemorrhagic Fevers (VHFs). Flavivirus" [Internet]. Atlanta: Centers for Disease Control and Prevention (CDC); p. 1. 2013.

[10]    Martina B.E.E., P. Koraka, and A.D.M.E. Osterhaus. "Dengue virus pathogenesis: An integrated view." *Clinical Microbiology Reviews*. vol. 22, issue 4, pp. 564–81. 2009.

[11]    Uno N., and T.M. Ross. "Dengue virus and the host innate immune response." *Emerging Microbes and Infections*. vol. 7, pp. 167. 2018.

[12]    Messina J.P., O.J. Brady, T.W. Scott, C. Zou, D.M. Pigott, K.A. Duda, et al. "Global spread of dengue virus types: Mapping the 70 year history." *Trends in Microbiology*. vol. 22, issue 3, pp. 138–46. 2014.

[13]    de Angel R.M., and J.R. del Valle. "Dengue Vaccines: Strongly Sought but Not a Reality Just Yet." *PLoS Pathogens*. vol. 9, issue 10, pp. 9–12. 2013.

[14]    Garcia M., M. Wehbe, N. Lévêque, and C. Bodet. "Skin innate immune response to flaviviral infection." *European Cytokine Network*. vol. 28, issue 2, pp. 41–51. 2017.

[15]    Samuel C.E. "Antiviral actions of interferons." *Clinical Microbiology Reviews*. vol. 14, issue 4, pp. 778–809. 2001.

[16]    Cha L., C.M. Berry, D. Nolan, A. Castley, S. Fernandez, and M. a French. "Interferon-alpha, immune activation and immune dysfunction in treated HIV infection." *Clinical & Translational Immunology*. vol. 3, issue 2, pp. e10. 2014.

[17]    Shereen M.A., S. Khan, A. Kazmi, N. Bashir, and R. Siddique. "COVID-19 infection:

Origin, transmission, and characteristics of human coronaviruses." *Journal of Advanced Research*. vol. 24, pp. 91–8. 2020.

[18] Laing K., and F. Hutchinson. "Immune Responses to Bacteria."

[19] Chapter T. "Chapter 13 – Immunity to Infection." Primer to the Immune Response. , pp. 295–332. 2014.

[20] Pulendran B., J.Z. Oh, H.I. Nakaya, R. Ravindran, and D.A. Kazmin. "Immunity to viruses: Learning from successful human vaccines." *Immunological Reviews*. vol. 255, issue 1, pp. 243–55. 2013.

[21] Hasan S., S.F. Jamdar, M. Alalowi, and S.M. Al Ageel Al Beaiji. "Dengue virus: A global human threat: Review of literature." *Journal of International Society of Preventive and Community Dentistry*. vol. 6, issue 1, pp. 1–6. 2016.

[22] St. John A.L. "Influence of Mast Cells on Dengue Protective Immunity and Immune Pathology." *PLoS Pathogens*. vol. 9, issue 12, pp. 1–4. 2013.

[23] Islam R., M. Salahuddin, M.S. Ayubi, T. Hossain, A. Majumder, A.W. Taylor-Robinson, et al. "Dengue epidemiology and pathogenesis: images of the future viewed through a mirror of the past." *Virologica Sinica*. vol. 30, issue 5, pp. 326–43. 2015.

[24] Rothman A.L., C.L. Medin, H. Friberg, and J.R. Currier. "Immunopathogenesis versus Protection in Dengue Virus Infections." *Current Tropical Medicine Reports*. vol. 1, issue 1, pp. 13–20. 2014.

[25] Wan S.W., B.A. Wu-Hsieh, Y.S. Lin, W.Y. Chen, Y. Huang, and R. Anderson. "The monocyte-macrophage-mast cell axis in dengue pathogenesis." *Journal of Biomedical Science*. vol. 25, issue 1, pp. 1–10. 2018.

[26] Negro F. "Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis?" *Swiss medical weekly*. vol. 150, issue April, pp. w20249. 2020.

[27] Ulrich H., M.M. Pillat, and A. Tárnok. "Dengue Fever, COVID-19 (SARS-CoV-2),

and Antibody-Dependent Enhancement (ADE): A Perspective." *Cytometry Part A*. vol. 19, issue 2, pp. 1–6. 2020.

[28]   Ministry of Health of the Republic of Indonesia. "COVID-19 Update until 28 July 2020." Jakarta; . 2020.

[29]   Nile S.H., A. Nile, J. Qiu, L. Li, X. Jia, and G. Kai. "COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons." *Cytokine and Growth Factor Reviews*. vol. 53, pp. 66–70. 2020.

[30]   Hu B., X. Ge, L.F. Wang, and Z. Shi. "Bat origin of human coronaviruses." *Virology Journal*. vol. 12, pp. 221. 2015.

[31]   De Wit E., N. Van Doremalen, D. Falzarano, and V.J. Munster. "SARS and MERS: Recent insights into emerging coronaviruses." *Nature Reviews Microbiology*. vol. 14, issue 8, pp. 523–34. 2016.

[32]   Mubarak A., W. Alturaiki, and M.G. Hemida. "Middle east respiratory syndrome coronavirus (mers-cov): Infection, immunological response, and vaccine development." *Journal of Immunology Research*. vol. 2019, issue Cdc. 2019.

[33]   Merad M., and J.C. Martin. "Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages." *Nature Reviews Immunology*. vol. 20, issue 6, pp. 355–62. 2020.

[34]   Wan Y., J. Shang, S. Sun, W. Tai, J. Chen, Q. Geng, et al. "Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry." *Journal of Virology*. vol. 94, issue 5, pp. 1–15. 2019.

[35]   Iwasaki A., and Y. Yang. "The potential danger of suboptimal antibody responses in COVID-19." *Nature Reviews Immunology*. vol. 20, issue 6, pp. 339–41. 2020.

[36]   Chen N., M. Zhou, X. Dong, J. Qu, F. Gong, Y. Han, et al. "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan,

China: a descriptive study." *The Lancet*. vol. 395, issue 10223, pp. 507–13. 2020.

[37]    Yan G., L. Pang, A.R. Cook, H.J. Ho, M.S. Win, A.L. Khoo, et al. "Distinguishing zika and dengue viruses through simple clinical assessment, Singapore." *Emerging Infectious Diseases*. vol. 24, issue 8, pp. 1565–8. 2018.

[38]    Yan G., C.K. Lee, L.T.M. Lam, B. Yan, Y.X. Chua, A.Y.N. Lim, et al. "Covert COVID-19 and false-positive dengue serology in Singapore." *The Lancet Infectious Diseases*. vol. 20, pp. 536. 2020.

[39]    Kraemer M.U.G., M.E. Sinka, K.A. Duda, A.Q.N. Mylne, F.M. Shearer, C.M. Barker, et al. "The global distribution of the arbovirus vectors Aedes aegypti and Ae. Albopictus." *eLife*. vol. 4, pp. e08347. 2015.

[40]    Kusriastuti R., and S. Sutomo. "Evolution of dengue prevention and control programme in Indonesia." *Dengue Bulletin*. vol. 29, pp. 1–7. 2005.

[41]    Ministry of Health of the Republic of Indonesia. "Beware of DHF, prevent with 3M Plus." Jakarta: Ministry of Health of the Republic of Indonesia; p. 1. 2020.

[42]    World Health Organization (WHO). "Infection prevention and control of epidemic- and pandemic-prone acute respiratory infections in health care" [Internet]. WHO Guidelines. Geneva: World Health Organization (WHO); , pp. 156. 2014.

[43]    Liu J., X. Liao, S. Qian, J. Yuan, F. Wang, Y. Liu, et al. "Community Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, Shenzhen, China, 2020." *Emerging infectious diseases*. vol. 26, issue 6, pp. 1320–3. 2020.

[44]    World Health Organizaton (WHO). "Advice on the use of masks in the context of COVID-19" [Internet]. Geneva: World Health Organizaton (WHO); , pp. 16. 2020.

[45]    Van Doremalen N., T. Bushmaker, D.H. Morris, M.G. Holbrook, A. Gamble, B.N. Williamson, et al. "Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1." *New England Journal of Medicine*. vol. 382, pp. 1564–7. 2020.

[46]    Wang W., Y. Xu, R. Gao, R. Lu, K. Han, G. Wu, et al. "Detection of SARS-CoV-2 in Different Types of Clinical Specimens." *JAMA - Journal of the American Medical Association*. vol. 323, issue 18, pp. 1843–4. 2020.

[47]    (WHO) W.H.O. "Transmission of SARS-CoV-2: implications for infection prevention precautions." Geneva; . 2020.

[48]    Huang S. "COVID-19: Why we should all wear masks - There is new scientific rationale" [Internet]. Medium; p. 10. 2020.

[49]    Ministry of Health of the Republic of Indonesia. "Minister of Health of the Republic of Indonesia Decree No. HK.01.07/Menkes/382/2020 about Health Protocol for Communities in Public Places and Facilities to Prevent and Control Corona Virus Disease 2019 (COVID-19)" [Internet]. Indonesia; p. 66. 2020.

# The Surge of Dengue Cases during COVID-19 in Indonesia

Publication

8    Achmad Fuad Hafid, Adita Ayu Permanasari, Lidya Tumewu, Myrna Adianti et al. "Activities of Ficus fistulosa Leave Extract and Fractions against Hepatitis C Virus", Procedia Chemistry, 2016
Publication                                                                1%

9    Ahmed A. Al-Qahtani. "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Emergence, history, basic and clinical aspects", Saudi Journal of Biological Sciences, 2020
Publication                                                               <1%

10   link.springer.com
Internet Source                                                          <1%

11   www.researchsquare.com
Internet Source                                                          <1%

12   worldwidescience.org
Internet Source                                                          <1%

13   Submitted to University of North Texas
Student Paper                                                            <1%

14   Miguel A. L. Nicolelis, Rafael L. G. Raimundo, Pedro S. Peixoto, Cecilia Siliansky de Andreazzi. "How super-spreader cities, highways, hospital bed availability, and dengue fever influenced the COVID-19 epidemic in
                                                                         <1%

Brazil", Cold Spring Harbor Laboratory, 2020
Publication

15  Aty Widyawaruyanti, Muhammad Asrory, Wiwied Ekasari, Dwi Setiawan, Achmad Radjaram, Lidya Tumewu, Achmad Fuad Hafid. "In vivo Antimalarial Activity of Andrographis Paniculata Tablets", Procedia Chemistry, 2014
Publication

<1 %

16  Submitted to uva
Student Paper

<1 %

17  David Y. Graham, Muhammad Miftahussurur. "Helicobacter pylori urease for diagnosis of Helicobacter pylori infection: A mini review", Journal of Advanced Research, 2018
Publication

<1 %

18  Submitted to University College London
Student Paper

<1 %

19  Submitted to Ain Shams University
Student Paper

<1 %

20  www.diabeticfootarchive.us
Internet Source

<1 %

21  clinicaltrials.gov
Internet Source

<1 %

22  www.mass.gov
Internet Source

<1 %

**23** www.faqs.org
Internet Source
<1 %

**24** www.annualreviews.org
Internet Source
<1 %

**25** www.esrnexus.com
Internet Source
<1 %

**26** reliefweb.int
Internet Source
<1 %

**27** Subodh Kumar Samrat, Anil M. Tharappel, Zhong Li, Hongmin Li. "Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development", Virus Research, 2020
Publication
<1 %

**28** Parth Goel, Dweepna Garg, Amit Ganatra. "Analytical Review of COVID-19 Outbreak in India During the Global Pandemic", Journal of Pure and Applied Microbiology, 2020
Publication
<1 %

# The Surge of Dengue Cases during COVID-19 in Indonesia

FINAL GRADE

/100

GENERAL COMMENTS

**Instructor**